RG 7236

Drug Profile

RG 7236

Alternative Names: RG7236

Latest Information Update: 17 Apr 2012

Price : $50

At a glance

  • Originator Roche
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 12 Apr 2012 Discontinued - Phase-I for Cardiovascular disorders in Switzerland (unspecified route)
  • 02 Feb 2011 Phase-I clinical trials in cardiovascular risk reduction [Cardiovascular disorders - prevention] in patients with chronic kidney disease in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top